Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate

Genes Chromosomes and Cancer

Volumn 47, Issue 7, 2008, Pages 565-572

  Bettendorf, Olaf ^a   Schmidt, Hartmut ^a   Staebler, Annette ^a   Grobholz, Rainer ^b   Heinecke, Achim ^a   Boecker, Werner ^a   Hertle, Lothar ^c   Semjonow, Axel ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ARTICLE; CHROMOSOME DISORDER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHROMOSOMAL INSTABILITY; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44349168861     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20560     Document Type: Article

References (37)

1. Bettendorf O, Schmidt H, Eltze E, Gockel I, Semjonow A, Bürger H, Böcker W, Brandt B. 2005. Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCR. Int J Oncol 26:267-274.
2. Bettendorf O, Oberpenning F, Köpke T, Heinecke A, Hertle L, Boecker W, Semjonow A. 2007. Implementation of a map in radical prostatectomy specimens allows visual estimation of tumor volume. Eur J Surg Oncol 33:352-357.
3. Bock BJ, Bostwick DG. 1999. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 23:781-785.
4. Bostwick DG, Dundore PA. 1997. Biopsy Pathology of the Prostate, 1st ed. New York: Chapman & Hall.
5. Bostwick DG, Liu L, Brawer MK, Qian J. 2004. High-grade prostatic intraepithelial neoplasia. Rev Urol 6:171-179.
6. Brawer MK. 2005. Prostatic intraepithelial neoplasia: An overview. Rev Urol 3:11-18.
7. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinckschmidt C, Dockhorn-Dworniczak B, Boecker W. 1999. Comparative genomic hybridization of ductal carcinoma in situ of the breast - Evidence of multiple genetic pathways. J Pathol 187:396-402.
8. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A. 1996. Semiautomated assessment of loss of heterozygosity and replication error in tumours. Cancer Res 56:3331-3337.
9. Capello F, Ribbene A, Campanella C, Czarnecka AM, Anzalone R, Bucchiere F, Palma A, Zummo G. 2006. The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: A review. Eur J Histochem 50:25-34.
10. Cohen RJ, Chan WC, Edgar SG, Robinson E, Dodd N, Hoscek S, Mundy IP. 1998. Prediction of pathological stage and clinical outcome in prostate cancer: An improved preoperative model incorporating biopsy-determined intraductal carcinoma. Br J Urol 81:413-418.
11. Cohen RJ, McNeal JE, Baillie T. 2000. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: Significance for cancer progression. Prostate 43:11-19.
12. Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA. 2007. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med 131:1103-1109.
13. Colombo P, Patriarca C, Alfano RM, Cassani B, Ceva Grimaldi G, Ronealli M, Bosari S, Coggi G, Campo B, Gould VE. 2001. Molecular disorders in transitional vs. peripheral zone prostate adenocarcinoma. Int J Cancer 94:383-389.
14. Dawkins HJS, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal JE, Cohen RJ. 2000. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive adenocarcinoma, using molecular markers of cancer progression. Prostate 44:265-270.
15. Downing SR, Russell PJ, Jackson P. 2003. Alterations of p53 are common in early stage prostate cancer. Can J Urol 10:1924-1933.
16. kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509-517.
17. Du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T. 1993. Detection of complete or partial chromosome gains and losses by comparartive genomic in situ hybridization. Hum Genet 90:590-610.
18. Epstein JI. 1992. Controversies in prostate pathology: Dysplasia and carcinoma in situ. Monogr Pathol 34:149-182.
19. Fenic I, Franke F, Failing K, Steger K, Woenckhaus J. 2004. Expression of PTEN in malignant and non-malignant human prostate tissues: Comparison with p27 protein expression. J Pathol 203:559-566.
20. Gleason DF, Mellinger GT. 1974. Prediction of prognosis for prostataic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64.
21. Guo CC, Epstein JI. 2006. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 19:1528-1535.
22. Hu CK, McCall S, Madden J, Huang H, Clough R, Jirtle RL, Anscher MS. 2006. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer Prostatic Dis 9:62-67.
23. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío IJ, Castresana JS. 2007. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 174:1-8.
24. Nikitin AY, Matoso A, Roy-Burman P. 2007. Prostate stem cells and cancer. Histol Histopathol 22:1053-1059.
25. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemus LP. 1994. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252-1257.
26. Quian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. 1995. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414.
27. Ribeiro FR, Diep CB, Jeronomo G, Lopes C, Eknaes M, Lingjaerde OC, Lothe RA, Teixeira MR. 2006. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 45:154-163.
28. Royuela M, Arenas MI, Bethencourt FR, Sánchez-Chapado M, Fraile B, Paniagua R. 2001. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 12:654-663.
29. Rubin MA, de la Taille A, Bagliella E, Olsson CA, O'Toole KM. 1998. Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: Incidence and clinical implications. Am J Surg Pathol 22:840-848.
30. Sattler H-P, Rhode V, Bonkhoff H, Zwergel T, Wullich B. 1999. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39:79-86.
31. Sauter G, Bubendorf L, Moch H, Gasser TC, Mihatsch MJ. 1998. Cytogenetic alterations in prostate cancer. Pathologe 19:63-68.
32. Sobin LH, Wittekind C. 2002. TNM Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss.
33. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. 1997. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158:131-137.
34. Wilcox G, Soh S, Chakraborty S, Scardino PT, Wheeler TM. 1998. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol 10:1119-1123.
35. Wolter H, Gottfried HW, Mattfeldt T. 2002. Genetic changes in stage pT2N0 prostate cancer studued bv comparative genomic hybridization. BJU Int 89:310-316.
36. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY. 2006. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898.
37. Zitzelsberger H, Kulka U, Lehmann L, Walch A, Smida J, Aubele M, Lörch T, Höfler H, Bauchinger M, Werner M. 1998. Genetic heterogeneity in a prostate carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch 433:297-304.